- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 204-218 of
249 results
2064 Exhibit: Correll et al, Effects of Olanzapine Combined With Samidorphan onW...
Document
IPR2020-01053, No. 2064 Exhibit - Correll et al, Effects of Olanzapine Combined With Samidorphan onWeight Gain in Schizophrenia (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2049 Exhibit: Seroquel Label
Document
IPR2020-01053, No. 2049 Exhibit - Seroquel Label (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2131 Exhibit: Declaration of Dr Stephen Stahl
Document
IPR2020-01053, No. 2131 Exhibit - Declaration of Dr Stephen Stahl (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2087 Exhibit: Mattingly et al, Switching to Lurasidone Following 12 Months ofTreatm...
Document
IPR2020-01053, No. 2087 Exhibit - Mattingly et al, Switching to Lurasidone Following 12 Months ofTreatment with Risperidone (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2061 Exhibit: Meltzer et al, Lurasidone in the Treatment of Schizophrenia ARandom...
Document
IPR2020-01053, No. 2061 Exhibit - Meltzer et al, Lurasidone in the Treatment of Schizophrenia ARandomized, Double Blind, Placebo and Olanzapine ControlledStudy (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2137 Exhibit: Weiden, Partial Compliance and Risk of Rehospitalization AmongCalif...
Document
IPR2020-01053, No. 2137 Exhibit - Weiden, Partial Compliance and Risk of Rehospitalization AmongCalifornia Medicaid Patients with Schizophrenia, PsychiatricServices (P.T.A.B. Mar. 11, 2021...
|
|
Cite Document
2068 Exhibit: Samalin et al, Clinical potential of lurasidone in the management ofsc...
Document
IPR2020-01053, No. 2068 Exhibit - Samalin et al, Clinical potential of lurasidone in the management ofschizophrenia (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2139 Exhibit: Tohen et al, Am J Psychiatry
Document
IPR2020-01053, No. 2139 Exhibit - Tohen et al, Am J Psychiatry (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2133 Exhibit: Declaration of Scott Stancell Condron
Document
IPR2020-01053, No. 2133 Exhibit - Declaration of Scott Stancell Condron (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2134 Exhibit: Deposition Transcript of Dr Thomas Kosten
Document
IPR2020-01053, No. 2134 Exhibit - Deposition Transcript of Dr Thomas Kosten (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2046 Exhibit: Kane et al Clozapine for the Treatment Resistant Schizophrenia
Document
IPR2020-01053, No. 2046 Exhibit - Kane et al Clozapine for the Treatment Resistant Schizophrenia (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2097 Exhibit: Poyurovsky et al, Attentuating Effect of Reboxetine on Appetite andW...
Document
IPR2020-01053, No. 2097 Exhibit - Poyurovsky et al, Attentuating Effect of Reboxetine on Appetite andWeight Gain in Olanzapine Treated Schizophrenia Patients (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2051 Exhibit: Thase, Quetiapine monotherapy for bipolar depression
Document
IPR2020-01053, No. 2051 Exhibit - Thase, Quetiapine monotherapy for bipolar depression (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
1001 Exhibit: EX 1001, US Patent No 9,815,827
Document
IPR2020-01053, No. 1001 Exhibit - EX 1001, US Patent No 9,815,827 (P.T.A.B. Jun. 5, 2020)
|
|
Cite Document
2077 Exhibit: Albright, Three key antipsychotics lose patent protection
Document
IPR2020-01053, No. 2077 Exhibit - Albright, Three key antipsychotics lose patent protection (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
